Company Leadership Changes - Ross Muken has been promoted to President of SOPHiA GENETICS, effective November 5, 2024, overseeing global business operations and strategic planning alongside CEO Jurgi Camblong [1][2] - George Cardoza has been appointed as the new CFO, responsible for all corporate finance functions including accounting, financial planning and analysis, investor relations, internal audit, tax, and treasury [2][3] Executive Backgrounds - Ross Muken joined SOPHiA GENETICS in February 2021 as CFO and became CFO and COO in March 2023, playing a key role in the company's success [1][2] - George Cardoza brings over 30 years of experience in the precision medicine and clinical diagnostics industry, having held executive roles at Biocartis and NeoGenomics Laboratories [3][4] Company Mission and Technology - SOPHiA GENETICS is a cloud-native healthcare technology company focused on expanding access to data-driven medicine using AI to provide care for patients with cancer and rare disorders [5] - The company developed SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data to generate actionable insights for hospitals, laboratories, and biopharma institutions [5]

Clinical growth reaccelerates with record analysis volume; Cash burn improves 39%BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial Results Revenue was $15.9 million, down 2.8% year-over-year Gross margins were 67.2% on a reported basis and 73.1% on an adjusted basis, compared to 69.1% and 72. ...

BOSTON and ROLLE, Switzerland, Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before U.S. markets open on Tuesday, November 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.The call will be webc ...

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzerland, Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI ...

The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY. SOPHiA UNITY is the global consortium announced at ASCO by SOPHiA GENETICS that connects best-in-class healthcare institutio ...

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland, Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and ...

Core Viewpoint - SOPHiA GENETICS SA (SOPH) has experienced a significant decline of 30.5% over the past four weeks, but it is now positioned for a potential trend reversal due to being in oversold territory and positive earnings expectations from Wall Street analysts [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2] - SOPH's current RSI reading is 17.38, suggesting that the heavy selling pressure may be exhausting, indicating a possible bounce back towards equilibrium [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for SOPH will improve, with a reported increase of 8.7% in the consensus EPS estimate over the last 30 days [6] - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [6] Group 3: Analyst Ratings - SOPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [7]

SOPHiA GENETICS SA (SOPH) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Individual inv ...

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 17.86%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.21, delivering a surprise of 16%. Over the last four quarters, the company has surpas ...

Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents | --- | --- | |-------|-----------------------------------------------------------------------------------------------------------------------------------| | | | | | Unaudited Interim Condensed Consolidated Financial Statements | | – | Unaudited Interim Condensed Consolidated Statements of Loss | | – | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss Unaudited Interim Condensed Consolidated Balance Sheets | | ...